Prognostic and clinicopathological roles of programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors: A meta-analysis
- Abstract
- BACKGROUND: Programmed death-ligand 1 (PD-L1) is one of the immune checkpoint proteins, and plays an important role in the progression and microenvironment of cancer. PD-L1 expression has been associated with poor survival in many cancers. Several studies have also shown an association between PD-L1 expression and the prognosis of patients with thymic epithelial tumors (TETs). In this study, we systematically evaluated the prognostic and clinicopathological roles of PD-L1 expression in TETs. METHODS: We searched the literature through PubMed, Embase and Cochrane library and chose the eligible studies, and subsequently performed a meta-analysis to evaluate the prognostic and clinicopathological roles of PD-L1 expression in TETs. RESULTS: Six of the 75 articles found in the literature were selected. PD-L1 expression was significantly related to unfavorable overall survival (hazard ratio 1.52, 95% confidence interval [CI]: 1.01-2.30, P = 0.046) in TETs. PD-L1 expression was significantly associated with male gender (odds ratio [OR] 1.55, 95% CI: 1.08-2.22, P = 0.017) and higher Masaoka stage (OR 3.93, 95% CI: 2.44-6.32, P < 0.001). CONCLUSIONS: PD-L1 expression was correlated with unfavorable prognosis in TETs, indicating PD-L1 expression could help determine the prognosis of TET patients.
- All Author(s)
- H. M. Koh
; B. G. Jang
; H. J. Lee
; C. L. Hyun
- Issued Date
- 2020
- Type
- Article
- Keyword
- Meta-analysis; prognosis; programmed death-ligand 1; thymic epithelial tumor
- Publisher
- International Chinese Society of Thoracic Surgery
- ISSN
- 1759-7706
; 1759-7714
- Citation Title
- Thoracic cancer
- Citation Volume
- 11
- Citation Number
- 11
- Citation Start Page
- 3086
- Citation End Page
- 3098
- Language(ISO)
- eng
- DOI
- 10.1111/1759-7714.13590
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/1909
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.